Vir Biotechnology (VIR) Stock Price, News & Analysis

Company Overview

Vir Biotechnology is a clinical-stage biopharmaceutical company focused on developing treatments for infectious diseases and cancer. Its research draws on immunology and includes approaches such as monoclonal antibodies, small-interfering RNA therapies and T-cell-based treatments.

The company’s pipeline has included programs targeting chronic hepatitis B and influenza, as well as investigational cancer therapies. Vir has also pursued research and development collaborations to advance its programs.

Historically, Vir partnered with GlaxoSmithKline to develop sotrovimab, an antibody treatment for COVID-19. Vir is headquartered in San Francisco, California.

Key Stats

• Today's Range: $9.71 to $10.70
• 50-Day Range: $9.96 to $13.65
• 52-Week Range: $5.32 to $14.38
• Volume: 16.66 million shs
• Average Volume: 1.92 million shs
• Market Capitalization: $1.71 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $22.57
• Consensus Rating: Moderate Buy

Vir Biotechnology Stock Analysis - MarketRank™

Vir Biotechnology scored higher than 48% of companies evaluated by MarketBeat, and ranked 579th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Vir Biotechnology has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 1 strong buy rating, 6 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Vir Biotechnology has a consensus price target of $22.57, representing about 126.6% upside from its current price of $9.96.

Amount of Analyst Coverage

Vir Biotechnology has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Vir Biotechnology are expected to decrease in the coming year, from ($1.28) to ($2.25) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Vir Biotechnology is -7.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Vir Biotechnology is -7.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Vir Biotechnology has a P/B Ratio of 1.90. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.15% of the float of Vir Biotechnology has been sold short.

Short Interest Ratio / Days to Cover

Vir Biotechnology has a short interest ratio ("days to cover") of 11.86, which indicates bearish sentiment.

Change versus previous month

Short interest in Vir Biotechnology has recently increased by 3.93%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Vir Biotechnology does not currently pay a dividend.

Dividend Growth

Vir Biotechnology does not have a long track record of dividend growth.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.53

News Sentiment

Vir Biotechnology has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 57 news articles for Vir Biotechnology this week, compared to 6 articles on an average week.

Search Interest

4 people have searched for VIR on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Vir Biotechnology to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 1.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Vir Biotechnology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $41,934.00 in company stock.

Percentage Held by Insiders

2.90% of the stock of Vir Biotechnology is held by insiders.

Percentage Held by Institutions

65.32% of the stock of Vir Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 11/04/2026
• Today: 11/13/2026
• Jefferies Global Healthcare Conference: 11/18/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:VIR
• CIK: 1706431
• Web: www.vir.bio
• Phone: 415-906-4324
• Fax: N/A
• Employees: 367
• Year Founded: 2016

Price Target and Rating

• Average Price Target for Vir Biotechnology: $22.57
• High Price Target: $30.00
• Low Price Target: $18.00
• Potential Upside/Downside: +126.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.78
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.26)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$437.99 million
• Net Margins: N/A
• Pretax Margin: -61.00%
• Return on Equity: -21.38%
• Return on Assets: -16.97%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.30
• Quick Ratio: 6.30

Sales & Book Value

• Annual Sales: $68.56 million
• Price / Sales: 24.88
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.23 per share
• Price / Book: 1.90

Miscellaneous

• Outstanding Shares: 171,270,000
• Free Float: 166,304,000
• Market Cap: $1.71 billion
• Optionable: Optionable
• Beta: 1.70